Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down16.540 -0.300 (-1.781%)
Research Report

14/04/2021 16:51

{I-bank focus}MS raises Hansoh Pharma (03692) to HK$51

[ET Net News Agency, 14 April 2021] Morgan Stanley raised its target price for Hansoh
Pharma (03692) to HK$51 from HK$50 and maintained its "overweight" rating.
The research house said it cuts its 2021-2023 earnings estimates by 2-7%, following the
earnings miss in 2H20, mainly due to centralized procurement price cuts on generic drugs.
But, given recent inclusions of three innovative drugs into the national reimbursement
list and multiple global licensing deals, it thinks that business visibility has
significantly improved. Hence, it extends the explicit forecast period by 7 years to end
at 2030. As a result, the price target and scenario values rise by 2-3%. (RC)

Remark: Real time quote last updated: 06/12/2021 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.